Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease - PubMed (original) (raw)
Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease
Miriam Merad et al. Nat Med. 2004 May.
Erratum in
- Nat Med. 2004 Jun;10(6):649
Abstract
Skin is the most commonly affected organ in graft-versus-host disease (GVHD). To explore the role of Langerhans cells in GVHD, the principal dendritic cells of the skin, we studied the fate of these cells in mice transplanted with allogeneic bone marrow. In contrast to other dendritic cells, host Langerhans cells were replaced by donor Langerhans cells only when donor T cells were administered along with bone marrow, and the extent of Langerhans cell chimerism correlated with the dose of donor T cells injected. Donor T cells depleted host Langerhans cells through a Fas-dependent pathway and induced the production in skin of CCL20, which was required for the recruitment of donor Langerhans cells. Administration of donor T cells to bone marrow-chimeric mice with persistent host Langerhans cells, but not to mice whose Langerhans cells had been replaced, resulted in marked skin GVHD. These findings indicate a crucial role for donor T cells in host Langerhans cell replacement, and show that host dendritic cells can persist in nonlymphoid tissue for the duration of an animal's life and can trigger GVHD despite complete blood chimerism.
Figures
Figure 1
Host Langerhans cells (LCs) persist in the skin after allogeneic stem cell transplantation. (a) BALB/c mice were reconstituted with low or high dose of TCD bone marrow (BM), purified HSCs, whole bone marrow or TCD bone marrow, together with peripheral blood (PB) T cells. Contour plots show percent of host and donor Langerhans cells in CD45+-gated epidermal cells after transplantation (Tx). (b) Percent of donor dendritic cells (DCs) and circulating monocytes (Mo) 4 weeks after transplantation. Mean of four separate experiments is shown. (c) Percent of host- and donor-derived Langerhans cells, 6–9 weeks after transplantation of TCD bone marrow alone or together with T cells purified from bone marrow, peripheral blood or spleen. (d,e) Epidermal cells were isolated 9 weeks after transplantation of 2 × 106 TCD bone marrow together with either 3 × 104 or 2 × 105 peripheral blood T cells. Contour plots (d) and bar graph (e) show percent of host- and donor-derived Langerhans cells. Results represent mean of two different experiments.
Figure 2
Allogeneic T cells deplete host Langerhans cells (LCs) through a Fas ligand–dependent pathway. BALB/c mice were injected with TCD bone marrow (BM), alone or with _gld, Prf1_−/− or wild-type (WT) peripheral blood T cells. (a) Proportion of donor and host Langerhans cells in epidermis 5 weeks after transplantation. (b,c) Percent host and donor Langerhans cells in epidermis (b), and donor T cells in skin (c) of recipient mice. Mean of three experiments is shown. (d–g) Histological examination 4 weeks after transplantation reveals normal skin in mice transplanted with TCD bone marrow alone (d) or together with gld T cells (e). Skin GVHD with necrotic keratinocytes and focal inflammatory infiltrate is seen in mice injected with _Prf1_−/− T cells (f), and severe GVHD with numerous necrotic keratinocytes and predominantly lymphoid inflammatory infiltrate is seen in mice injected with wild-type T cells (g). Magnification, ×200. (h) Dot plots show percentage of host dendritic cells (DCs) among gated CD11c+ cells in mesenteric lymph nodes (MLNs) and peripheral skin-draining (inguinal) lymph nodes (PLNs) at 4 and 8 months after transplantation. One of two experiments is shown.
Figure 3
Expression of CCR2 and CCR6 on donor bone marrow (BM) cells is required for Langerhans cell (LC) chimerism. (a) Fold increase of relative levels of chemokine transcripts in skin of treated mice compared with nontransplanted BALB/c control mice. Data represent mean of two different experiments. (b–d) Mice were injected with either _Ccr2_−/− or Ccr2+/+ (b), a 1:1 mixture of CD45.2+ _Ccr2_−/− and CD45.1+ Ccr2+/+ or CD45.2+ Ccr2+/+ and CD45.1+ Ccr2+/+ cells (c), or _Ccr6_−/− or Ccr6+/+ TCD bone marrow (d), alone or in addition to wild-type (WT) T cells. Results shown are mean of three separate experiments. (e,f) Mice were transplanted as described in c and d. Source of spleen dendritic cells (DCs), T cells and monocytes (Mo) was determined 5 weeks later.
Figure 4
Host Langerhans cells (LCs) that persist in chimeric mice induce severe skin GVHD. BALB/c mice were reconstituted with whole C57BL/6 bone marrow (BM) or TCD bone marrow, lethally irradiated 8 weeks later, and injected again with TCD bone marrow and T cells from C57BL/6 mice. Plots show percentage of infiltrating donor T cells in skin (a) and percentage of host and donor LCs in CD45+-gated epidermal cells (b), before and 3 and 5 weeks after second transplantation (Tx). (c,d) Histological examination 4 weeks after second transplant reveals severe (grade 4) GVHD, characterized by extensive apoptosis of basal keratinocytes, vacuolization and infiltration of inflammatory cells, in mice that had only host Langerhans cells at time of second transplantation (c). No skin GVHD was observed in mice that had full Langerhans cell chimerism at time of the second transplant (d). Results shown are representative of two separate mice. Magnification, ×200.
Figure 5
Depletion of host Langerhans cells (LCs) prevents skin GVHD. (a) BALB/c mice were reconstituted with C57BL/6 TCD bone marrow (BM) and either left untreated or exposed to ultraviolet (UV) light. Six weeks after ultraviolet exposure, all mice were reconstituted with TCD bone marrow and T cells from C57BL/6 mice. (b) Contour plots show percentage of host and donor Langerhans cells in gated PI− epidermal cells 3 weeks after exposure to ultraviolet light. (c–e) Skin sections obtained 3 weeks after second transplant and stained with H&E are shown at ×200 magnification. Mice not previously reconstituted with TCD bone marrow but exposed to ultraviolet light (c) and mice previously reconstituted with TCD bone marrow, but not exposed to ultraviolet light (d), show extensive mononuclear infiltrates in superficial dermis that focally infiltrate epidermis, associated with necrotic keratinocytes and vacuolization of basal keratinocytes (grade 2 GVHD). Mice previously reconstituted with TCD bone marrow and exposed to ultraviolet light (e) lack infiltrates in skin, and show only rare necrotic keratinocytes (grade 0.5 GVHD).
Comment in
- Tanning before transplant: lancing the Langerhans cell.
Emerson SG. Emerson SG. Nat Med. 2004 May;10(5):451-2. doi: 10.1038/nm0504-451. Nat Med. 2004. PMID: 15122238 No abstract available.
Similar articles
- Donor T cells lacking Fas ligand and perforin retain the capacity to induce severe GvHD in minor histocompatibility antigen mismatched bone-marrow transplantation recipients.
Marks L, Altman NH, Podack ER, Levy RB. Marks L, et al. Transplantation. 2004 Mar 27;77(6):804-12. doi: 10.1097/01.tp.0000110416.96307.d5. Transplantation. 2004. PMID: 15077018 - CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, Negrin RS. Edinger M, et al. Nat Med. 2003 Sep;9(9):1144-50. doi: 10.1038/nm915. Epub 2003 Aug 17. Nat Med. 2003. PMID: 12925844 - The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice.
Baker MB, Altman NH, Podack ER, Levy RB. Baker MB, et al. J Exp Med. 1996 Jun 1;183(6):2645-56. doi: 10.1084/jem.183.6.2645. J Exp Med. 1996. PMID: 8676085 Free PMC article. - Immunopathology of cutaneous graft-versus-host disease.
Breathnach SM, Katz SI. Breathnach SM, et al. Am J Dermatopathol. 1987 Aug;9(4):343-8. doi: 10.1097/00000372-198708000-00009. Am J Dermatopathol. 1987. PMID: 2443033 Review. - Role of dendritic cells and chemokines in acute graft-versus-host disease.
Xu J, Zhou T, Zhang Y. Xu J, et al. Front Biosci. 2008 Jan 1;13:2065-74. doi: 10.2741/2824. Front Biosci. 2008. PMID: 17981692 Review.
Cited by
- Risk factors for graft-versus-host-disease after donor lymphocyte infusion following T-cell depleted allogeneic stem cell transplantation.
Koster EAS, von dem Borne PA, van Balen P, Marijt EWA, Tjon JML, Snijders TJF, van Lammeren D, Veelken H, Falkenburg JHF, Halkes CJM, de Wreede LC. Koster EAS, et al. Front Immunol. 2024 Mar 13;15:1335341. doi: 10.3389/fimmu.2024.1335341. eCollection 2024. Front Immunol. 2024. PMID: 38545096 Free PMC article. - Complex interactions of cellular players in chronic Graft-versus-Host Disease.
Gail LM, Schell KJ, Łacina P, Strobl J, Bolton SJ, Steinbakk Ulriksen E, Bogunia-Kubik K, Greinix H, Crossland RE, Inngjerdingen M, Stary G. Gail LM, et al. Front Immunol. 2023 Jun 26;14:1199422. doi: 10.3389/fimmu.2023.1199422. eCollection 2023. Front Immunol. 2023. PMID: 37435079 Free PMC article. Review. - A Phenotypic Analysis of Involucrin-Membrane-Bound Ovalbumin Mice after Adoptive Transfer of Ovalbumin-Specific CD8+ T Cells.
Nakagawa Y, Egawa G, Miyake T, Nakajima S, Otsuka A, Nomura T, Kitoh A, Dainichi T, Sakabe JI, Shibaki A, Tokura Y, Honda T, Kabashima K. Nakagawa Y, et al. JID Innov. 2022 Mar 30;2(5):100127. doi: 10.1016/j.xjidi.2022.100127. eCollection 2022 Sep. JID Innov. 2022. PMID: 36090298 Free PMC article. - STR typing of skin swabs from individuals after an allogeneic hematopoietic stem cell transplantation.
von Máriássy D, Reibke R, Verbeek M, Gätjens B, Schiller R, Anslinger K. von Máriássy D, et al. Int J Legal Med. 2023 Jan;137(1):227-236. doi: 10.1007/s00414-022-02847-5. Epub 2022 Jun 3. Int J Legal Med. 2023. PMID: 35657433 Free PMC article. - Innate Immune Determinants of Graft-Versus-Host Disease and Bidirectional Immune Tolerance in Allogeneic Transplantation.
Hamers AAJ, Joshi SK, Pillai AB. Hamers AAJ, et al. OBM Transplant. 2019;3(1):10.21926/obm.transplant.1901044. doi: 10.21926/obm.transplant.1901044. Epub 2019 Jan 31. OBM Transplant. 2019. PMID: 33511333 Free PMC article.
References
- Teshima T, Ferrara JL. Understanding the alloresponse: new approaches to graft-versus-host disease prevention. Semin. Hematol. 2002;39:15–22. - PubMed
- Goker H, Haznedaroglu IC, Chao NJ. Exp. Hematol. 2001;29:259–277. - PubMed
- Ferrara JL, Levy R, Chao NJ. Pathophysiologic mechanisms of acute graft-vs.-host disease. Biol. Blood Marrow Transplant. 1999;5:347–356. - PubMed
- Ho VT, Soiffer RJ. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood. 2001;98:3192–3204. - PubMed
- Shlomchik WD, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 1999;285:412–415. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous